InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
December 20 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the development,
manufacturing and commercialization of rare cannabinoids, today
announced that a peer-reviewed scientific article entitled
“Cannabinol Modulates Neuroprotection and Intraocular Pressure: A
Potential Multi-Target Therapeutic Intervention for Glaucoma”, has
been published in
Biochimica et Biophysical Acta (BBA -
Molecular Basis of Disease), a leading international
journal focused on biochemistry and molecular genetics of disease
processes and models of human disease in the area of aging, cancer,
metabolic-, neurological-, and immunological-based diseases.
The peer-reviewed article highlights research
evaluating the use of cannabinol, or CBN, as a potential treatment
option for glaucoma. Several studies were conducted to evaluate the
survival of retinal ganglion cells, modulation of intraocular
pressure and its effects on extracellular matrix proteins using in
vitro and in vivo glaucoma models.
These studies resulted in two key findings:
first, CBN may promote neuroprotection of cells in the retina that
are responsible for vision; and second, CBN may normalize
intraocular pressure by attenuating changes in the extracellular
matrix proteins. The article also reports on the comparison of CBN
with other cannabinoids, including cannabidiol (CBD) and
tetrahydrocannabinol (THC), with results indicating that CBN has a
stronger effect and broader neuroprotective therapeutic range.
These observations elucidate the therapeutic potential for CBN in
the treatment of glaucoma.
“Having this research peer-reviewed and
published in such a reputable journal is a significant milestone
for InMed’s glaucoma development program. This provides important
external validation for the scientific community as the program
advances towards human studies”, said InMed’s scientific advisor,
Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the
Department of Biotechnological and Applied Clinical Sciences,
University of L’Aquila, Italy. “We believe InMed’s INM-088 program
has significant implications for neuroprotection within the
glaucoma space and may lead to a potential new treatment for
millions of people suffering from this condition worldwide.”
Corresponding author Professor Ujendra Kumar,
Faculty of Pharmaceuticals, The University of British Columbia,
added; “The observations in this study indicate the therapeutic
potential for the use of CBN in the treatment of glaucoma. Not only
does the data suggest a reduction in ocular pressure but also
proactive neuroprotection in the retina, both of which are integral
to the treatment of glaucoma. This publication is further evidence
to suggest rare cannabinoids have therapeutic potential to treat
various diseases.”
The journal article can be accessed here:
https://doi.org/10.1016/j.bbadis.2021.166325
About Glaucoma: Glaucoma is a group of eye
diseases which result in damage to the optic nerve due to high
intraocular pressure (IOP) of the eye from fluid build-up.
According to the American Academy of Ophthalmology, glaucoma is the
leading cause of blindness in adults aged 60 and older. It is
estimated that 76 million people worldwide have glaucoma. There is
a major unmet medical need for new glaucoma treatments that provide
neuroprotection of retinal ganglion cells. Current treatments work
to reduce intraocular pressure but do not provide direct
neuroprotection in the retina.
About CBN: Cannabinol (CBN) is a
non-intoxicating rare cannabinoid. It is one of the more than 140
cannabinoid compounds present in the Cannabis plant. CBN is also
the active pharmaceutical ingredient in InMed’s lead program,
INM-755 cannabinol cream, which is currently undergoing a Phase 2
Clinical Trial in the treatment of Epidermolysis Bullosa
(“EB”). In several preclinical safety pharmacology and toxicology
studies using CBN at high doses, no adverse events were seen on
central nervous system (CNS) function in a rigorous evaluation of
108 CNS measurements.
Learn about InMed’s INM-088, a CBN topical
formulation for the treatment of glaucoma:
https://www.inmedpharma.com/pharmaceutical/inm-088-for-glaucoma/
Learn more about cannabinol:
https://www.inmedpharma.com/learn/what-is-cannabinol/
About InMed: InMed
Pharmaceuticals is a global leader in the development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary, BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is a clinical-stage company developing a pipeline of rare
cannabinoid therapeutics and dedicated to delivering new treatment
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: a topical eye drop formulation under
development for the treatment of glaucoma; CBN promoting
neuroprotection of the eye and normalizing intraocular pressure and
the potential to treat millions suffering from glaucoma; the
potential for rare cannabinoids to treat various diseases; being a
global leader in the manufacturing and development of rare
cannabinoids; and delivering new treatment alternatives to patients
that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024